Mark Lowdell

Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the Company in September 2015.   Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994.  Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust.   He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.